Literature DB >> 220119

Theophylline: biochemical pharmacology and pharmacokinetics.

P W Trembath, S W Boobis, A Richens.   

Abstract

Theophylline and its derivatives, such as aminophylline, have an established role as bronchodilators, although their mode of action in man is not clear. There is circumstantial evidence that therapeutic doses of theophylline may have a phosphodiesterase inhibiting effect, thus potentiating the effects of cyclic AMP. However, it remains to be established whether this is the primary mode of action of theophylline at the biochemical level. The pathways of theophylline metabolism have been clarified, although most of the enzymes involved have not been characterized. Hepatic microsomal enzyme induction by polycyclic hydrocarbons will increase the rate of theophylline elimination. There are a number of factors which influence theophylline clearance in adults, which is known to be highly variable. These factors include obesity, smoking habit, diet and the presence of such diseases as hepatic cirrhosis, acute pulmonary oedema, cor pulmonale and viral respiratory infection. There is a good correlation between plasma theophylline level and bronchodilator effect. This can be demonstrated at plasma levels as low as 5 microgram/ml, although optimal levels are usually greater than 10 microgram/ml. Unacceptable toxicity usually occurs in association with plasma levels greater than 20 microgram/ml. The maintenance of adequate plasma theophylline levels by the use of a sustained-release aminophylline tablet is discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 220119

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  7 in total

1.  Slow release choline theophyllinate (Sabidal SR 270) in chronic asthma.

Authors:  S J Berg; L P Balant; I Clarke; A J Fairfax
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

2.  Sustained release oral aminophylline in patients with airflow obstruction.

Authors:  A P Greening; E Baillie; H R Gribbin; N B Pride
Journal:  Thorax       Date:  1981-04       Impact factor: 9.139

3.  Serum theophylline--a mandatory measurement in the control of therapy?

Authors:  M S Laher; P O'Regan; F Jackson; E MacCarthy; E Wright; T B Counihan; P Keelan
Journal:  Ir J Med Sci       Date:  1985-05       Impact factor: 1.568

4.  Acute and chronic pharmacokinetics of asymmetrical doses of slow release choline theophyllinate in asthma.

Authors:  S G Hibberd; C Alveyn; E J Coombes; S T Holgate
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

5.  Comparison between the effects of inhaled isoprenaline and fenoterol on plasma cyclic AMP and heart rate in normal subjects.

Authors:  A J Fairfax; M Rehahn; D Jones; B O'Malley
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

6.  Slow-release oral salbutamol and aminophylline in nocturnal asthma: relation of overnight changes in lung function and plasma drug levels.

Authors:  A J Fairfax; W R McNabb; H J Davies; S G Spiro
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

7.  Oral sustained-release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations.

Authors:  L E Ramsay; A Mackay; M L Eppel; J S Oliver
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.